Effect of adjuvant chemotherapy in stage III cervical cancer patients treated with concurrent chemoradiation: A multicenter study

dc.authoridOrçun Can / 0000-0002-9400-105Xen_US
dc.authorscopusidOrçun Can / 57204774164
dc.authorwosidOrçun Can / AGX-9627-2022en_US
dc.contributor.authorAtci, Muhammed Mustafa
dc.contributor.authorAkagunduz, Baran
dc.contributor.authorDemir, Metin
dc.contributor.authorDönmez Yilmaz, Binnur
dc.contributor.authorAkin Telli, Tugba
dc.contributor.authorCan, Orçun
dc.contributor.authorCil, Ibrahim
dc.contributor.authorGoktas Aydın, Sabin
dc.contributor.authorOzyurt, Neslihan
dc.contributor.authorOnder, Arif Hakan
dc.contributor.authorSelvi, Oguzhan
dc.contributor.authorSakin, Abdullah
dc.date.accessioned2022-05-31T08:30:26Z
dc.date.available2022-05-31T08:30:26Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractIntroduction: A significant proportion of cervical cancer (CC) patients are diagnosed at a locally advanced stage. Concurrent chemoradiotherapy (CCRT) is the cornerstone of treatment for patients with locally advanced CC. However, the role of adjuvant chemotherapy (AC) after CCRT is controversial. In this study, we analyzed the efficacy of AC after CCRT in stage III CC patients. Methods: We performed a multicenter, retrospective analysis of 139 International Federation of Gynecology and Obstetrics stage III CC patients treated with CCRT of whom 45.3% received AC. Our goal was to determine the impact of AC on survival in these patients. Results: Five-year progression-free survival (PFS) was 37.5% and 16% in patients receiving CCRT with and without AC, respectively (p = 0.008). Median PFS was 30.9 months (CI 95% 14.8-46.9) and 16.6 months (CI 95% 9.3-23.9) in patients receiving CCRT with and without AC, respectively. Five-year overall survival (OS) was 78.2% and 28.4% in patients receiving CCRT with and without AC, respectively (p < 0.001). Median OS was 132.2 months (CI 95, %66.5-197.8) and 34.9 months (CI 95% 23.1-46.7) in patients receiving CCRT with and without AC, respectively. Conclusion: Our study suggests that AC provides OS and PFS benefit in stage III CC patients. Larger studies are needed to identify subgroups of patients who would benefit from AC.en_US
dc.identifier.citationAtci MM, Akagunduz B, Demir M, Dönmez Yilmaz B, Akin Telli T, Can O, Cil I, Goktas Aydın S, Ozyurt N, Onder AH, Selvi O, Sakin A. Effect of Adjuvant Chemotherapy in Stage III Cervical Cancer Patients Treated with Concurrent Chemoradiation: A Multicenter Study. Oncol Res Treat. 2022;45(5):254-261. doi: 10.1159/000521980. Epub 2022 Jan 14. PMID: 35034017.en_US
dc.identifier.doi10.1159/000521980en_US
dc.identifier.endpage261en_US
dc.identifier.issue5en_US
dc.identifier.pmid35034017en_US
dc.identifier.scopus2-s2.0-85129996780en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage254en_US
dc.identifier.urihttp://doi.org/ 10.1159/000521980
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2760
dc.identifier.volume45en_US
dc.identifier.wosWOS:000833355100003en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorCan, Orçun
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofOncology Research and tTeatmenten_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCervical Canceren_US
dc.subjectAdjuvant Chemotherapyen_US
dc.subjectStage IIIen_US
dc.titleEffect of adjuvant chemotherapy in stage III cervical cancer patients treated with concurrent chemoradiation: A multicenter studyen_US
dc.typeArticleen_US

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: